Currently dependent on any substance other than cannabis, alcohol or nicotine;
History of any major internal disease (including diabetes, cardiovascular disease, lung disease, liver or kidney disease);
An active or any history of neurological disorder, including but not limited to seizure disorder, epilepsy, stroke, neurological disease, cognitive impairment, head trauma with prolonged loss of consciousness (>10 minutes), or migraine headaches;
An active or a history of a psychiatric disorder including, but not limited to, depression, schizophrenia, bipolar disorder, anxiety, or other psychiatric disorders;
Asthma;
Known hypersensitivity or allergy to n-acetylcysteine, or receiving chronic therapy with medication that could interact adversely with n-acetylcysteine within 30 days prior to randomization (i.e., nitroglycerin, ACE inhibitors or antihypertensive drugs, anti-coagulants);
Exclusion criteria for MRI: having metal in the body and/or having claustrophobia

NCT03221231_exc_T1
Condition
dependent
NCT03221231_exc_T2
Drug
substance
NCT03221231_exc_T3
Negation
other than
NCT03221231_exc_T4
Drug
cannabis
NCT03221231_exc_T5
Drug
alcohol
NCT03221231_exc_T6
Drug
nicotine
NCT03221231_exc_T7
Scope
cannabis, alcohol or nicotine
NCT03221231_exc_T8
Condition
major internal disease
NCT03221231_exc_T9
Condition
diabetes
NCT03221231_exc_T10
Condition
cardiovascular disease
NCT03221231_exc_T11
Condition
lung disease
NCT03221231_exc_T12
Condition
kidney disease
NCT03221231_exc_T13
Condition
iver isease)
NCT03221231_exc_T14
Scope
diabetes, cardiovascular disease, lung disease, liver or kidney disease
NCT03221231_exc_T15
Condition
neurological disorder
NCT03221231_exc_T16
Observation
history
NCT03221231_exc_T17
Qualifier
active
NCT03221231_exc_T18
Scope
active or any history
NCT03221231_exc_T19
Condition
seizure disorder
NCT03221231_exc_T20
Condition
epilepsy
NCT03221231_exc_T21
Condition
stroke
NCT03221231_exc_T22
Condition
neurological disease
NCT03221231_exc_T23
Condition
cognitive impairment
NCT03221231_exc_T24
Condition
head trauma
NCT03221231_exc_T25
Condition
prolonged loss of consciousness
NCT03221231_exc_T26
Qualifier
>10 minutes
NCT03221231_exc_T27
Condition
migraine headaches
NCT03221231_exc_T28
Scope
seizure disorder, epilepsy, stroke, neurological disease, cognitive impairment, head trauma with prolonged loss of consciousness (>10 minutes), or migraine headaches
NCT03221231_exc_T29
Qualifier
active
NCT03221231_exc_T30
Observation
history
NCT03221231_exc_T31
Condition
psychiatric disorder
NCT03221231_exc_T32
Condition
depression
NCT03221231_exc_T33
Condition
schizophrenia
NCT03221231_exc_T34
Condition
bipolar disorder
NCT03221231_exc_T35
Condition
anxiety
NCT03221231_exc_T36
Condition
psychiatric disorders
NCT03221231_exc_T37
Qualifier
other
NCT03221231_exc_T38
Scope
depression, schizophrenia, bipolar disorder, anxiety, or other psychiatric disorders
NCT03221231_exc_T39
Scope
active or a history
NCT03221231_exc_T40
Condition
Asthma
NCT03221231_exc_T41
Condition
hypersensitivity
NCT03221231_exc_T42
Condition
allergy
NCT03221231_exc_T43
Drug
n-acetylcysteine
NCT03221231_exc_T44
Scope
hypersensitivity or allergy
NCT03221231_exc_T45
Procedure
chronic therapy
NCT03221231_exc_T46
Drug
n-acetylcysteine
NCT03221231_exc_T47
Temporal
within 30 days prior to randomization
NCT03221231_exc_T48
Drug
nitroglycerin
NCT03221231_exc_T49
Drug
ACE inhibitors
NCT03221231_exc_T50
Drug
antihypertensive drugs
NCT03221231_exc_T51
Drug
anti-coagulants
NCT03221231_exc_T52
Scope
nitroglycerin, ACE inhibitors or antihypertensive drugs, anti-coagulants
NCT03221231_exc_T53
Condition
Exclusion criteria for MRI
NCT03221231_exc_T54
Device
metal in the body
NCT03221231_exc_T55
Condition
claustrophobia
NCT03221231_exc_T56
Scope
metal in the body and/or having claustrophobia